Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00530621 · ClinicalTrials.gov registry record · Phase 2
Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
NCT00530621 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 160 participants.
The verdict
NCT00530621, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer (NSCLC).
Interventions
- DRUG placebo
- DRUG pemetrexed
- DRUG enzastaurin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2007-09 |
| Est. Completion | 2008-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00530621
The ClinicalTrials.gov registry entry for NCT00530621 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00530621 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00530621 about?
NCT00530621 is a clinical study titled "Study of Enzastaurin Versus Placebo With Pemetrexed for Participants With Advanced or Metastatic Lung Cancer". The purpose of this study is to determine if the combination of enzastaurin and pemetrexed can extend survival time without progression of disease for participants who have advanced or metastatic non-small cell lung cancer (NSCLC).
What is the current status of trial NCT00530621?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2007-09. Estimated completion is 2008-10.
What interventions are being tested in trial NCT00530621?
The interventions under investigation include: placebo (DRUG), pemetrexed (DRUG), enzastaurin (DRUG).
Who is sponsoring clinical trial NCT00530621?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.